Cargando…

A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses

BACKGROUND: Nanovaccines have shown the promising potential in controlling and eradicating the threat of infectious diseases worldwide. There has been a great need in developing a versatile strategy to conveniently construct diverse types of nanovaccines and induce potent immune responses. To that e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sisi, Yang, Liu, Ou, Xia, Li, Jin-Yu, Zi, Cheng-Ting, Wang, Hao, Hu, Jiang-Miao, Liu, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281129/
https://www.ncbi.nlm.nih.gov/pubmed/35836236
http://dx.doi.org/10.1186/s12951-022-01533-3
_version_ 1784746810810564608
author Chen, Sisi
Yang, Liu
Ou, Xia
Li, Jin-Yu
Zi, Cheng-Ting
Wang, Hao
Hu, Jiang-Miao
Liu, Ye
author_facet Chen, Sisi
Yang, Liu
Ou, Xia
Li, Jin-Yu
Zi, Cheng-Ting
Wang, Hao
Hu, Jiang-Miao
Liu, Ye
author_sort Chen, Sisi
collection PubMed
description BACKGROUND: Nanovaccines have shown the promising potential in controlling and eradicating the threat of infectious diseases worldwide. There has been a great need in developing a versatile strategy to conveniently construct diverse types of nanovaccines and induce potent immune responses. To that end, it is critical for obtaining a potent self-adjuvant platform to assemble with different types of antigens into nanovaccines. RESULTS: In this study, we identified a new natural polysaccharide from the rhizomes of Bletilla striata (PRBS), and used this polysaccharide as a platform to construct diverse types of nanovaccines with potent self-adjuvant property. In the construction process of SARS-CoV-2 nanovaccine, PRBS molecules and RBD protein antigens were assembled into ~ 300 nm nanoparticles by hydrogen bond. For HIV nanovaccine, hydrophobic effect dominantly drove the co-assembly between PRBS molecules and Env expression plasmid into ~ 350 nm nanospheres. Importantly, PRBS can potently activate the behaviors and functions of multiple immune cells such as macrophages, B cells and dendritic cells. Depending on PRBS-mediated immune activation, these self-adjuvant nanovaccines can elicit significantly stronger antigen-specific antibody and cellular responses in vivo, in comparison with their corresponding traditional vaccine forms. Moreover, we also revealed the construction models of PRBS-based nanovaccines by analyzing multiple assembly parameters such as bond energy, bond length and interaction sites. CONCLUSIONS: PRBS, a newly-identified natural polysaccharide which can co-assemble with different types of antigens and activate multiple critical immune cells, has presented a great potential as a versatile platform to develop potent self-adjuvant nanovaccines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01533-3.
format Online
Article
Text
id pubmed-9281129
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92811292022-07-14 A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses Chen, Sisi Yang, Liu Ou, Xia Li, Jin-Yu Zi, Cheng-Ting Wang, Hao Hu, Jiang-Miao Liu, Ye J Nanobiotechnology Research BACKGROUND: Nanovaccines have shown the promising potential in controlling and eradicating the threat of infectious diseases worldwide. There has been a great need in developing a versatile strategy to conveniently construct diverse types of nanovaccines and induce potent immune responses. To that end, it is critical for obtaining a potent self-adjuvant platform to assemble with different types of antigens into nanovaccines. RESULTS: In this study, we identified a new natural polysaccharide from the rhizomes of Bletilla striata (PRBS), and used this polysaccharide as a platform to construct diverse types of nanovaccines with potent self-adjuvant property. In the construction process of SARS-CoV-2 nanovaccine, PRBS molecules and RBD protein antigens were assembled into ~ 300 nm nanoparticles by hydrogen bond. For HIV nanovaccine, hydrophobic effect dominantly drove the co-assembly between PRBS molecules and Env expression plasmid into ~ 350 nm nanospheres. Importantly, PRBS can potently activate the behaviors and functions of multiple immune cells such as macrophages, B cells and dendritic cells. Depending on PRBS-mediated immune activation, these self-adjuvant nanovaccines can elicit significantly stronger antigen-specific antibody and cellular responses in vivo, in comparison with their corresponding traditional vaccine forms. Moreover, we also revealed the construction models of PRBS-based nanovaccines by analyzing multiple assembly parameters such as bond energy, bond length and interaction sites. CONCLUSIONS: PRBS, a newly-identified natural polysaccharide which can co-assemble with different types of antigens and activate multiple critical immune cells, has presented a great potential as a versatile platform to develop potent self-adjuvant nanovaccines. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01533-3. BioMed Central 2022-07-14 /pmc/articles/PMC9281129/ /pubmed/35836236 http://dx.doi.org/10.1186/s12951-022-01533-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Sisi
Yang, Liu
Ou, Xia
Li, Jin-Yu
Zi, Cheng-Ting
Wang, Hao
Hu, Jiang-Miao
Liu, Ye
A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
title A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
title_full A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
title_fullStr A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
title_full_unstemmed A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
title_short A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
title_sort new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281129/
https://www.ncbi.nlm.nih.gov/pubmed/35836236
http://dx.doi.org/10.1186/s12951-022-01533-3
work_keys_str_mv AT chensisi anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT yangliu anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT ouxia anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT lijinyu anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT zichengting anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT wanghao anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT hujiangmiao anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT liuye anewpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT chensisi newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT yangliu newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT ouxia newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT lijinyu newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT zichengting newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT wanghao newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT hujiangmiao newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses
AT liuye newpolysaccharideplatformconstructsselfadjuvantnanovaccinestoenhanceimmuneresponses